--- title: "Ondine Biomedical (LON:OBI) Sets New 12-Month Low - Here's What Happened" type: "News" locale: "en" url: "https://longbridge.com/en/news/273367064.md" description: "Ondine Biomedical (LON:OBI) shares hit a new 52-week low of C$7.50, last trading at C$8.00 with a volume of 89,210 shares. The stock's 50-day moving average is C$9.79, and the 200-day moving average is C$12.56. The company has a market cap of C$4.15 billion and a price-to-earnings ratio of -1.14. Analysts currently rate the stock as a Hold, but it is not among the top recommended stocks by analysts." datetime: "2026-01-22T11:48:12.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/273367064.md) - [en](https://longbridge.com/en/news/273367064.md) - [zh-HK](https://longbridge.com/zh-HK/news/273367064.md) --- # Ondine Biomedical (LON:OBI) Sets New 12-Month Low - Here's What Happened Shares of Ondine Biomedical Inc. (LON:OBI - Get Free Report) hit a new 52-week low on Thursday . The stock traded as low as C$7.50 and last traded at C$8.00, with a volume of 89210 shares traded. The stock had previously closed at C$8.00. Get **Ondine Biomedical** alerts: ## Ondine Biomedical Price Performance The business's 50 day moving average is C$9.79 and its 200-day moving average is C$12.56. The stock has a market cap of C$4.15 billion, a price-to-earnings ratio of -1.14 and a beta of 0.10. The company has a debt-to-equity ratio of 25.95, a quick ratio of 8.26 and a current ratio of 1.36. ## About Ondine Biomedical (Get Free Report) Ondine Biomedical is a life sciences company leading the charge in breakthrough photodisinfection-based therapies to prevent and treat serious infections, including those caused by existing, emerging, and antimicrobial-resistant pathogens. Our vision is a world free from infections. We have created a patented, platform technology (photodisinfection) to provide simple solutions to complex infections across different therapeutic areas in healthcare and industry settings. We are focused on solutions that address significant needs, are easy to deploy, are environmentally safe, provide substantial public health benefits, and cost a fraction of the infections they target. Our photodisinfection technology has been used successfully for many years in more than 100,000 patient treatments in hospitals, clinics, and industrial settings across Canada. ## Featured Articles - Five stocks we like better than Ondine Biomedical - Wall Street Alert: Buy AES - Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why - Trump’s Hand-Written Letter Will Shock his Haters - Bitcoin is down but your income is about to explode - A month before the crash _This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com._ ## Should You Invest $1,000 in Ondine Biomedical Right Now? Before you consider Ondine Biomedical, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ondine Biomedical wasn't on the list. While Ondine Biomedical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [LABD.US](https://longbridge.com/en/quote/LABD.US.md) - [OCEA.US](https://longbridge.com/en/quote/OCEA.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [OCEAW.US](https://longbridge.com/en/quote/OCEAW.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [ONCY.US](https://longbridge.com/en/quote/ONCY.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) ## Related News & Research - [Relay drug shows early promise against rare blood vessel diseases](https://longbridge.com/en/news/287094432.md) - [14:05 ETLupin Receives Tentative Approval from U.S. FDA for Revefenacin Inhalation Solution](https://longbridge.com/en/news/286805922.md) - [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md) - [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md) - [Eton Pharmaceuticals Adds Another 2026 Launch As It Secures U.S. Rights To IMPAVIDO](https://longbridge.com/en/news/287025596.md)